science
An instinct about Atavistik? Roche signs $1.9B-plus deal
Privately held Atavistik Bio Inc. chalked a research collaboration with Roche AG to discover and develop small-molecule therapeutics against multiple targets for cardiovascular, renal and metabolic diseases.
ONLY AVAILABLE IN PAID PLANS
Read Full ArticleShare this story
Up next
Related Stories

Practitioner-researchers in social care and social work – hope for the future or promises unfulfilled?
Lse Blogs | Expert Analysis From Lse, The World-le

AMRC Rotor Spin Tester
University Of Sheffield

Young minds develop ideas to tackle climate change
The Bbc

Exploring efficiency and durability in fuel cell catalysts
Physicsworld

NASA's Low-Earth Orbit Economy Faces Crisis as SpaceX Moves Beyond Crew Dragon: Here's Why
Techtimes